In8Bio Inc (INAB) Stock Price, Quote & News

Company Profile

IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its products include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product ca...

Industry: Biotechnology

Sector: Healthcare

Phone: 646 600 6438

Website: in8bio.com

Address:

350 5th Avenue, Suite 5330, New York, United States

ZekeBalderdash Feb. 18 at 7:57 PM

$INAB A pretty compelling account of the glioblastoma results: https://x.com/In8bio/status/2023900531832266752?s=20. I still think they'll need more data for AA, but maybe the FDA will agree with Ho.

0 · Reply

aletz Feb. 18 at 6:58 PM

$INAB https://www.biostockinfo.com/in8bio-inab-update-the-cash-crisis-is-over-now-the-real-question-begins/ Update on my DD on INAB, especially trying to understand INB-619 better. @IN8bio let me know if my understanding is correct.

3 · Reply

NarrativeNavigator Feb. 18 at 3:26 PM

$INAB In8bio is an early-stage cell therapy biotech focused on oncology with binary development risk. Valuation is driven almost entirely by clinical progress rather than near-term revenue. Cash runway and trial timelines define downside risk.

0 · Reply

IN8bio Feb. 17 at 11:21 PM

How we’re pushing innovation in oncology. We're just getting started $INAB https://x.com/In8bio/status/2023900531832266752

0 · Reply

PortfolioOdyssey Feb. 17 at 1:31 PM

$INAB Pre-revenue biotech; early-stage.

0 · Reply

SkywalkerAR Feb. 14 at 12:01 AM

$INAB

0 · Reply

IN8bio Feb. 13 at 10:22 PM

This is our path towards Cancer Zero $INAB https://x.com/In8bio/status/2022436143271403639

0 · Reply

aletz Feb. 13 at 4:46 PM

$INAB Conference is just the CEO reading out cooperate presentation. Nothing to be excited about. Patience is key.

0 · Reply

Dont_Forget_The_Dates Feb. 13 at 1:55 PM

$INAB

0 · Reply

you_no Feb. 13 at 12:06 AM

$INAB Did you have a conference? Why haven't I heard anything?

0 · Reply

IN8bio Promotes Kate Rochlin, Ph.D., to President and Chief Operating Officer

Feb 3, 2026, 8:00 AM EST - 20 days ago

IN8bio to Present at Upcoming Investor and Scientific Conferences in February

Jan 12, 2026, 8:00 AM EST - 6 weeks ago

IN8bio Presents Updated Phase I/II Data Demonstrating Meaningful and Durable Survival Improvements in Newly Diagnosed Glioblastoma

Dec 19, 2025, 8:00 AM EST - 2 months ago

IN8bio Announces Pricing of Private Placement of up to $40.2 Million to Advance Novel Gamma-Delta T Cell Engager

Nov 6, 2025, 4:00 PM EST - 3 months ago

IN8bio Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Oct 29, 2025, 8:00 AM EDT - 4 months ago

IN8bio Expands INB-100 Phase 1 Clinical Trial with Addition of The Ohio State University as New Site

Oct 27, 2025, 8:00 AM EDT - 4 months ago

IN8bio Presents T cell Engager Data Demonstrating Deep B Cell Depletion for Autoimmune Indications

Aug 7, 2025, 4:00 PM EDT - 7 months ago

IN8bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Jun 9, 2025, 7:00 AM EDT - 9 months ago

IN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblastoma Trial

Jun 2, 2025, 7:30 AM EDT - 9 months ago

IN8bio Presents Positive Phase 1 Data of INB-200 in Newly Diagnosed GBM Demonstrating Prolonged Progression-Free Survival

May 14, 2025, 8:00 AM EDT - 10 months ago

IN8bio Presents Preclinical Data Highlighting Potential of INB-619 T Cell Engager (TCE) for Autoimmune Disease at ASGCT 2025

May 12, 2025, 8:00 AM EDT - 10 months ago

IN8bio Presents Data at ISCT 2025 Demonstrating Proprietary γδ T cell Manufacturing Generates Consistent and Robust Clinical Products

May 7, 2025, 4:00 PM EDT - 10 months ago

IN8bio Reports First Quarter 2025 Financial Results and Recent Business Highlights

Apr 29, 2025, 8:00 AM EDT - 10 months ago

IN8bio to Present Clinical and Preclinical Data from Gamma-Delta T Cell Platform at Upcoming Scientific Conferences

Apr 28, 2025, 8:00 AM EDT - 10 months ago

IN8bio Unveils Promising New Data from Next Generation Gamma-Delta T Cell Engager (TCE) Platform at AACR 2025

Mar 31, 2025, 8:00 AM EDT - 11 months ago

IN8bio to Present New Preclinical Data on Novel Gamma-Delta (γδ) T cell Engager Platform for Cancer Immunotherapy at AACR Annual Meeting 2025

Mar 18, 2025, 8:05 AM EDT - 1 year ago

IN8bio to Participate at the 11th Annual Immuno-Oncology 360° Conference 2025

Mar 13, 2025, 4:05 PM EDT - 1 year ago

IN8bio Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights

Mar 3, 2025, 9:28 AM EST - 1 year ago

IN8bio Announces Advanced Gamma-Delta (γδ) T cell Engager (TCE) Platform for Oncology and Autoimmune Diseases

Feb 26, 2025, 8:00 AM EST - 1 year ago

IN8bio to Present at the TD Cowen 45th Annual Health Care Conference

Feb 24, 2025, 8:00 AM EST - 1 year ago

IN8bio to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

Feb 14, 2025, 9:00 AM EST - 1 year ago

IN8bio Presents Positive Phase 1 Data at TCT 2025, Highlighting Durability of Remissions in High-Risk AML

Feb 11, 2025, 8:00 AM EST - 1 year ago

IN8bio Reports Updated Positive Results from Phase 1 Trial of INB-100 in Leukemia Patients

Dec 10, 2024, 7:00 AM EST - 1 year ago

IN8bio Reports Continued Progression-Free Survival in Phase 1 Investigator-Sponsored Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 American Society of Hematology Annual Meeting

Nov 12, 2024, 4:26 PM EST - 1 year ago

IN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

Sep 4, 2024, 4:01 PM EDT - 1 year ago

IN8bio Announces Clinical Pipeline Prioritization to Focus on INB-100 for Acute Myeloid Leukemia

Aug 29, 2024, 6:05 AM EDT - 1 year ago

IN8bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 12, 2024, 8:05 AM EDT - 1 year ago

IN8bio Solidifies Position as a Clinical Leader of Gamma-Delta T Cell Therapy in Oncology with 100% of Treated AML Patients in Complete Remission and Receives FDA Guidance for Registrational Trial of INB-100

Jun 24, 2024, 8:00 AM EDT - 1 year ago

IN8bio to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

Jun 13, 2024, 4:01 PM EDT - 1 year ago

IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100

Jun 3, 2024, 6:05 AM EDT - 1 year ago

IN8bio Presents Progression-Free Survival Update from Phase 1 Study of INB-200 at 2024 American Society of Clinical Oncology Annual Meeting

May 24, 2024, 8:00 AM EDT - 1 year ago

IN8bio to Present at International Society for Cell & Gene Therapy (ISCT) 2024

May 23, 2024, 5:00 PM EDT - 1 year ago

IN8bio Announces INB-200 Phase 1 Study Data in Newly Diagnosed Glioblastoma to be Presented at the 2024 ASCO Annual Meeting

May 14, 2024, 10:00 AM EDT - 1 year ago

IN8bio Announces Upcoming Presentation at 2024 European Hematology Association Congress

May 13, 2024, 8:00 AM EDT - 1 year ago

IN8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation at ASGCT 2024

May 9, 2024, 4:00 PM EDT - 1 year ago

IN8bio Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

Apr 30, 2024, 6:05 AM EDT - 1 year ago

IN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed Glioblastoma

Apr 24, 2024, 8:00 AM EDT - 1 year ago

IN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

Apr 16, 2024, 4:05 PM EDT - 2 years ago

IN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference

Apr 9, 2024, 4:30 PM EDT - 2 years ago

IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024

Mar 14, 2024, 4:00 PM EDT - 2 years ago

IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights

Mar 5, 2024, 4:30 PM EST - 2 years ago

IN8bio to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024

Feb 26, 2024, 8:00 AM EST - 2 years ago

IN8bio to Present at Upcoming Investor Conferences

Feb 14, 2024, 8:00 AM EST - 2 years ago

IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology

Jan 4, 2024, 8:00 AM EST - 2 years ago

IN8bio Highlights Recent Company Accomplishments and Outlines 2024 Pipeline Goals

Dec 11, 2023, 4:05 PM EST - 2 years ago

IN8bio Announces Positive Clinical Update Demonstrating Continued Durable Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 in Leukemia

Dec 11, 2023, 9:00 AM EST - 2 years ago

IN8bio Announces Pricing of Financing Totaling up to $46.9 Million in Private Placement

Dec 7, 2023, 8:00 AM EST - 2 years ago

IN8bio Appoints Dr. Corinne Epperly to Board of Directors

Dec 5, 2023, 8:00 AM EST - 2 years ago

IN8bio to Host Investor Call at 8:30 AM ET on Tuesday, December 12 to Discuss Updated Clinical Data from Phase 1 Trial of INB-100 in Patients with Leukemia

Nov 20, 2023, 7:00 AM EST - 2 years ago

IN8bio's INB-200 Demonstrates Extended Progression-Free Survival in Patients with Newly Diagnosed Glioblastoma

ZekeBalderdash Feb. 18 at 7:57 PM

$INAB A pretty compelling account of the glioblastoma results: https://x.com/In8bio/status/2023900531832266752?s=20. I still think they'll need more data for AA, but maybe the FDA will agree with Ho.

0 · Reply

aletz Feb. 18 at 6:58 PM

3 · Reply

NarrativeNavigator Feb. 18 at 3:26 PM

0 · Reply

IN8bio Feb. 17 at 11:21 PM

How we’re pushing innovation in oncology. We're just getting started $INAB https://x.com/In8bio/status/2023900531832266752

0 · Reply

PortfolioOdyssey Feb. 17 at 1:31 PM

$INAB Pre-revenue biotech; early-stage.

0 · Reply

SkywalkerAR Feb. 14 at 12:01 AM

$INAB

0 · Reply

IN8bio Feb. 13 at 10:22 PM

This is our path towards Cancer Zero $INAB https://x.com/In8bio/status/2022436143271403639

0 · Reply

aletz Feb. 13 at 4:46 PM

$INAB Conference is just the CEO reading out cooperate presentation. Nothing to be excited about. Patience is key.

0 · Reply

Dont_Forget_The_Dates Feb. 13 at 1:55 PM

$INAB

0 · Reply

you_no Feb. 13 at 12:06 AM

$INAB Did you have a conference? Why haven't I heard anything?

0 · Reply

OfficialStocktwitsUser Feb. 12 at 8:37 PM

$INAB RSI: 23.81, MACD: -0.0586 Vol: 0.22, MA20: 2.11, MA50: 2.01 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

SkywalkerAR Feb. 12 at 5:59 AM

$INAB

0 · Reply

IN8bio Feb. 11 at 9:40 PM

Welcome to the future of oncology $INAB

1 · Reply

YoloAlfred Feb. 10 at 9:56 PM

$INAB 1/2 phase data readout

1 · Reply

IN8bio Feb. 10 at 1:12 AM

Exciting news at $INAB! We're proud to announce Kate Rochlin, Ph.D., as our new President and Chief Operating Officer! “Kate has been instrumental in translating IN8bio’s strategy into disciplined execution,” said William Ho, Chief Executive Officer and Co-Founder of IN8bio. “I am confident that her promotion to President will further strengthen the organization.” Congratulations, Kate! 🎉 Read More: https://bit.ly/3ZKtxlP

0 · Reply

3ARated Feb. 9 at 8:36 PM

$INAB Probably drop before any news on Thursday. Just a guess, I would think a catalyst would be some sort of Fastrack with FDA.

0 · Reply

SentinelStocks Feb. 9 at 3:36 PM

$INAB Immunology biotech; early-stage pipeline, high risk.

0 · Reply

DARKP00L Feb. 9 at 1:11 PM

$INAB 08:08 on Feb. 09 2026 IN8bio Promotes Kate Rochlin To President, COO, Effective Immediately #tradeideas

0 · Reply

SkywalkerAR Feb. 6 at 6:14 PM

$INAB IO360° Conference Date: Thursday, February 12, 2026 Time: 1:20 p.m. – 1:40 p.m. ET Session: IO Clinical Advancements Plenary Presentation title: IN8bio’s Unique DeltEx Drug Resistant Immunotherapy (DRI) Approach to Solid Tumors & Results from Phase 1/2 Study in Newly Diagnosed GBM very important day

0 · Reply

lv20 Feb. 6 at 6:01 PM

$INAB any updates on this stock?

0 · Reply

IN8bio Feb. 6 at 4:07 PM

Between major updates, what’s most useful for you to hear from a biotech team? $INAB

3 · Reply

IN8bio Feb. 5 at 6:31 PM

Cancer cells watching our therapy approach $INAB

0 · Reply

Market Cap	15.14M
Revenue (ttm)	0.00
Net Income (ttm)	-30.44M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	15,100
Avg Vol	330,802
Day's Range	N/A - N/A
Shares Out	9.77M
Stochastic %K	5%
Beta	-0.01
Analysts	Strong Sell
Price Target	$5.00